Heregulin inhibits proliferation via ERKs and phosphatidyl-inositol 3-kinase activation but regulates urokinase plasminogen activator independently of these pathways in metastatic mammary tumor cells

Autor: Puricelli, L., Proiettii, C.J., Labriola, L., Salatino, M., Balañá, M.E., Ghiso, J.A., Lupu, R., Pignataro, O.P., Charreau, E.H., De Joffé, E.B.K., Elizalde, P.V.

Publikováno v: Int. J. Cancer 2002;100(6):642-653
Biblioteca Digital (UBA-FCEN)
Universidad Nacional de Buenos Aires. Facultad de Ciencias Exactas y Naturales
instacron:UBA-FCEN

Heregulin (HRG) and type I receptor tyrosine kinase (RTK) expression was investigated in the highly invasive and metastatic LM3 cell line, our previously described model of metastasis for mammary cancer (Bal de Kier Joffe et al. [1986] Invasion Metas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3056::6764e93e41e09f0c3110f08d48fbf20e